MONDAY, May 21, 2018 (HealthDay News) -- Aimovig (erenumab-aooe) has been approved by the U.S. Food and Drug Administration to prevent migraine headaches in adults.
Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule involved in migraine attacks, the agency said in a news release.
"Aimovig provides patients with a novel option for reducing the number of days with migraine," Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "We need new treatments for this painful and often debilitating condition."
Aimovig was evaluated in clinical studies involving more than 2,000 people. Over the course of the studies, patients treated with Aimovig experienced, on average, one to two fewer monthly migraine days, compared to participants taking a placebo. The drug's most common side effects included injection-site reactions and constipation.
Aimovig is produced by Amgen Inc., based in Thousand Oaks, Calif.
This article: Copyright © 2018 HealthDay. All rights reserved.